Study on the metabolism of 5,6-methylenedioxy-2-aminoindane (MDAI) in rats: identification of urinary metabolites
- PMID: 27401914
- DOI: 10.1080/00498254.2016.1199919
Study on the metabolism of 5,6-methylenedioxy-2-aminoindane (MDAI) in rats: identification of urinary metabolites
Erratum in
-
Correction to: Study on the metabolism of 5,6-methylenedioxy-2-aminoindane (MDAI) in rats: identification of urinary metabolites.Xenobiotica. 2017 Jun;47(6):x. doi: 10.1080/00498254.2017.1307576. Xenobiotica. 2017. PMID: 28424018 No abstract available.
Abstract
1. 5,6-Methylenedioxy-2-aminoindane (MDAI) is a member of aminoindane drug family with serotoninergic effect, which appeared on illicit drug market as a substitute for banned stimulating and entactogenic drugs. 2. Metabolism of MDAI, which has been hitherto unexplored, was studied in rats dosed with a subcutaneous dose of 20 mg MDAI.HCl/kg body weight. The urine of rats was collected within 24 h after dosing for analyses by HPLC-ESI-HRMS and GC/MS. 3. The main metabolic pathways proceeding in parallel were found to be oxidative demethylenation followed by O-methylation and N-acetylation. These pathways gave rise to five metabolites, namely, 5,6-dihydroxy-2-aminoindane, 5-hydroxy-6-methoxy-2-aminoindane, N-acetyl-5,6-methylenedioxy-2-aminoindane, N-acetyl-5,6-dihydroxy-2-aminoindane and N-acetyl-5-hydroxy-6-methoxy-2-aminoindane, which were found predominantly in the form of corresponding glucuronides and sulphates. However, the main portion of administered MDAI was excreted unchanged. 4. Minor metabolites formed primarily by hydroxylation at various sites include cis- and trans-1-hydroxy-5,6-methylenedioxy-2-aminoindane, 5,6-methylenedioxyindan-2-ol and 4-hydroxy-5,6-methylenedioxy-2-aminoindane. 5. Identification of all metabolites except for glucuronides, sulphates and tentatively identified 4-hydroxy-5,6-methylenedioxy-2-aminoindane was supported by synthesised reference standards.
Keywords: Biotransformation in rats; GC–MS; LC-HRMS; MDAI; new designer drugs; urinary metabolites.
Similar articles
-
Biotransformation and detectability of the new psychoactive substances N,N-diallyltryptamine (DALT) derivatives 5-fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT in urine using GC-MS, LC-MSn, and LC-HR-MS/MS.Anal Bioanal Chem. 2017 Feb;409(6):1681-1695. doi: 10.1007/s00216-016-0117-5. Epub 2016 Dec 8. Anal Bioanal Chem. 2017. PMID: 27933361
-
MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; 'sparkle'; 'mindy') toxicity: a brief overview and update.Hum Psychopharmacol. 2013 Jul;28(4):345-55. doi: 10.1002/hup.2298. Hum Psychopharmacol. 2013. PMID: 23881883 Review.
-
Emerging toxicity of 5,6-methylenedioxy-2-aminoindane (MDAI): Pharmacokinetics, behaviour, thermoregulation and LD50 in rats.Prog Neuropsychopharmacol Biol Psychiatry. 2016 Aug 1;69:49-59. doi: 10.1016/j.pnpbp.2016.04.004. Epub 2016 Apr 12. Prog Neuropsychopharmacol Biol Psychiatry. 2016. PMID: 27083855
-
Identification of three new phase II metabolites of a designer drug methylone formed in rats by N-demethylation followed by conjugation with dicarboxylic acids.Xenobiotica. 2018 Jun;48(6):618-625. doi: 10.1080/00498254.2017.1349964. Epub 2017 Jul 25. Xenobiotica. 2018. PMID: 28665175
-
Aminoindanes--the next wave of 'legal highs'?Drug Test Anal. 2011 Jul-Aug;3(7-8):479-82. doi: 10.1002/dta.318. Epub 2011 Jul 11. Drug Test Anal. 2011. PMID: 21748859 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous